Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year.

导出 LinkOut

翻译打印收藏纠错

作者： Arash,Mostaghimi ^[1] ; Matthias,Augustin ^[2] ; Kazutoshi,Harada ^[3] ; Maryanne,Senna ^[4] ; Yves,Dutronc ^[5] ; Guanglei,Yu ^[5] ; Susan,Ball ^[5] ; Mwangi,Murage ^[5] ; Jill,Kolodsick ^[5] ; Yiying,Brogan ^[6] ; Brett,King ^[7]

作者单位： Brigham and Women's Hospital, Boston, Massachusetts, USA. ^[1] Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. ^[2] Department of Dermatology, Tokyo Medical University, Tokyo, Japan. ^[3] Lahey Dermatology, Burlington, Massachusetts, USA.;Harvard Medical School, Boston, Massachusetts, USA. ^[4] Eli Lilly and Company, Indianapolis, Indiana, USA. ^[5] Tiger Med Group, Wayne, New Jersey, USA. ^[6] Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. ^[7]

DOI 10.1111/jdv.20334

PMID 39569884

发布时间 2024-11-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of the European Academy of Dermatology and Venereology

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year.

Journal of the European Academy of Dermatology and Venereology

相似文献

Journal of the European Academy of Dermatology and Venereology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year.

Journal of the European Academy of Dermatology and Venereology

相似文献

Journal of the European Academy of Dermatology and Venereology

相关期刊

检索历史清除